Effect of combination therapy of specific active immunization and aclacinomycin-A on murine myeloid leukemia.
D015250:Aclarubicin; D000818:Animals; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D007114:Immunization; D007942:Leukemia, Experimental / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000401:mortality / Q000628:therapy; D051379:Mice; D009279:Naphthacenes / Q000627:therapeutic use; D014411:Neoplastic Stem Cells; D013154:Spleen / Q000166:cytology; D013156:Splenectomy
D009279:Naphthacenes; D015250:Aclarubicin